Xinli formula's efficacy in heart failure: analysis via Guangdong TCM hospital database

Front Pharmacol. 2025 Nov 17;16:1661625. doi: 10.3389/fphar.2025.1661625. eCollection 2025.

ABSTRACT

OBJECTIVE: To evaluate the efficacy of the "Xinli Formula" in improving cardiac function, symptoms, and quality of life in patients with heart failure using a hospital database.

METHODS: A retrospective study included 210 patients (2017-2022) divided into Xinli Formula group (n = 107) and non-Xinli Formula group (n = 103). Outcomes included cardiac function parameters, N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, 6-min walk distance (6MWD), quality of life (Minnesota Living with Heart Failure Questionnaire, MLHFQ), and inflammatory markers. Data were analyzed using SPSS 26.0.

RESULTS: The Xinli Formula group showed significant improvements in Left Ventricular Ejection Fractions (LVEF) (38% → 42%), Left Ventricular End-Systolic Diameter (LVESD) (45 mm → 40 mm), Left Ventricular End-Diastolic Diameter (LVEDD) (60 mm → 55 mm), and 6MWD (350 m → 400 m). MLHFQ scores decreased from 45 to 30. Inflammatory markers and NT-proBNP levels also improved significantly.

CONCLUSION: The Xinli Formula significantly improves cardiac function, exercise tolerance, and quality of life in patients with heart failure and may be an effective adjunctive therapy. Further studies are needed.

PMID:41333015 | PMC:PMC12665773 | DOI:10.3389/fphar.2025.1661625